MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors
Katrine Ingelshed(Karolinska Institutet), Diana Spiegelberg(Uppsala University)
Cited by 14
Related Papers
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth <i>In Vivo</i> and Potentiates Radiotherapy
|Cancer Research Communications|2022|14
The Novel Anti-cMet Antibody seeMet 12 Potentiates Sorafenib Therapy and Radiotherapy in a Colorectal Cancer Model
|Frontiers in Oncology|2020|6